<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Timothy S Olson, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter Newburger, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 08, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Aplastic anemia (AA) is a life-threatening form of bone marrow failure which, if untreated, is associated with very high mortality. AA refers to pancytopenia in association with bone marrow hypoplasia/aplasia, most often due to immune injury to multipotent hematopoietic stem cells. The term "aplastic anemia" is a misnomer because the disorder is characterized by pancytopenia rather than anemia alone.
        </p>
        <p>
         This topic will review the epidemiology, pathogenesis, clinical manifestations, evaluation, diagnosis, and differential diagnosis of AA. Our approach to the evaluation and diagnosis of AA is consistent with published guidelines [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         The following topics are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">
          "Approach to the adult with pancytopenia"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7158.html" rel="external">
          "Treatment of aplastic anemia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4065498351">
         <span class="h1">
          DEFINITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         AA refers to pancytopenia in association with bone marrow hypoplasia/aplasia, and has diverse underlying causes  (
         <a class="graphic graphic_table graphicRef70072" href="/z/d/graphic/70072.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. Criteria for the diagnosis of AA are described below. (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         below.)
        </p>
        <p>
         Bone marrow failure is a broader term, in which cytopenias may be caused by bone marrow replacement (eg, by tumor or fibrosis) or myelodysplastic syndromes  (
         <a class="graphic graphic_table graphicRef52354" href="/z/d/graphic/52354.html" rel="external">
          table 2
         </a>
         ), in addition to other various causes of AA.
        </p>
        <p class="headingAnchor" id="H4048392768">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         AA is a rare disorder. In Western countries the incidence is approximately two per million per year and the incidence is estimated to be two- to threefold higher in Asia [
         <a href="#rid4">
          4-8
         </a>
         ]. The sex ratio of AA is close to 1:1 in almost all population-based studies. Half of cases of AA occur in the first three decades of life.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Loss of hematopoietic stem cells (HSC) is a defining feature of AA.
        </p>
        <p class="headingAnchor" id="H1042398337">
         <span class="h2">
          Hematopoietic stem cells
         </span>
         <span class="headingEndMark">
          —
         </span>
         HSCs in the bone marrow are the source of all mature cells in the peripheral blood and tissues. HSCs are multipotent (ie, can give rise to diverse cellular lineages) and generally quiescent. HSCs have the capacity for self-renewal (thereby sustaining a lifelong store of HSCs) and give rise to committed progenitor cells, which have reduced lineage potential but high proliferative capacity. Through successive mitotic divisions, progenitor cells ultimately produce fully mature blood cells.
        </p>
        <p>
         HSCs are not morphologically identifiable (they resemble lymphoid cells), but they can be recognized and isolated based on their characteristic immunophenotype. HSCs constitute a small population within the CD34+/CD38– fraction of bone marrow cells. HSCs can also be detected in the peripheral blood, from which they can be isolated for use in hematopoietic cell transplantation.
        </p>
        <p class="headingAnchor" id="H4248053426">
         <span class="h2">
          Pathogenic mechanisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         AA is associated with loss of HSCs and the resultant decrease in mature blood cells. When the HSC pool falls below a critical mass, the conflicting demands of self-renewal and differentiation can lead to pancytopenia.
        </p>
        <p>
         Pathophysiologic processes that lead to loss of HSCs and cause AA include [
         <a href="#rid9">
          9
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autoimmune mechanisms
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Direct injury to HSCs (eg, by drugs, chemicals, irradiation)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Viral infection
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clonal and genetic disorders
        </p>
        <p>
        </p>
        <p>
         Autoimmune damage to HSCs causes or contributes to most cases of AA, whether another underlying cause is identified or not. It is hypothesized that drugs, chemicals, viruses, or mutations alter the immunologic appearance of HSCs and lead to autoimmune destruction/suppression. This hypothesis is supported by clinical observations, laboratory correlative studies, animal models, and the responsiveness of AA to immune suppression [
         <a href="#rid10">
          10-14
         </a>
         ].
        </p>
        <p>
         Cytotoxic lymphocytes and type I cytokines appear to be proximate effectors of autoimmune aplasia in AA, but there is also evidence of deficient quantity and/or function of T-regulatory cells [
         <a href="#rid15">
          15,16
         </a>
         ]. Interferon gamma (IFN gamma), other cytokines (eg, IL-17), natural killer cells, and autoantibodies have also been implicated in immune destruction of HSCs in AA [
         <a href="#rid17">
          17-23
         </a>
         ].
        </p>
        <p>
         IFN gamma initiates a cytokine cascade and induces the Fas receptor, and both are implicated in increased apoptotic death of HSCs in AA [
         <a href="#rid17">
          17,18,24-30
         </a>
         ]. IFN gamma is detected in the bone marrow of patients with acquired AA, and disappears in response to immunosuppression [
         <a href="#rid31">
          31
         </a>
         ]. In one report, 96 percent of patients with circulating IFN gamma-containing T cells subsequently responded to immunosuppressive therapy, while only 32 percent who lacked IFN gamma-containing lymphocytes improved; 12 of 13 subjects in whom IFN gamma was present during relapse responded to reinstitution of immunosuppressive agents [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         AA is occasionally associated with certain conditions in which the mechanism of HSC loss is poorly understood. Examples include anorexia nervosa (often associated with gelatinous degeneration and serous fat atrophy of bone marrow), pregnancy, and as a complication of orthotopic liver transplantation (especially in the context of fulminant hepatic failure). (See
         <a class="medical medical_review" href="/z/d/html/14705.html" rel="external">
          "Anorexia nervosa in adults and adolescents: Medical complications and their management", section on 'Hematologic'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H62533888">
         <span class="h2">
          Clonal evolution
         </span>
         <span class="headingEndMark">
          —
         </span>
         AA may coexist with or evolve into another hematologic disorder (eg, paroxysmal nocturnal hemoglobinuria [PNH], myelodysplastic syndromes [MDS], acute myeloid leukemia [AML]).
        </p>
        <p>
         There is controversy about whether specific treatments of AA foster clonal evolution. A meta-analysis and a randomized trial did not detect an association between the development of PNH, MDS, or AML and treatment with immunosuppression plus growth factors [
         <a href="#rid33">
          33,34
         </a>
         ]. Earlier observational studies that reported such a link could not distinguish association from causality [
         <a href="#rid35">
          35-40
         </a>
         ].
        </p>
        <p>
         Clonal evolution in AA may be detected by the acquisition of mutations or cytogenetic abnormalities. Examples include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most commonly mutated genes include
         <em>
          DMNT3A
         </em>
         ,
         <em>
          ASXL1,
         </em>
         <em>
          BCOR,
         </em>
         <em>
          BCORL1,
         </em>
         and
         <em>
          PIGA
         </em>
         [
         <a href="#rid41">
          41
         </a>
         ]. Some of the mutations are the same as those seen in hematopoietic cells of healthy older individuals without a hematologic disorder (ie, clonal hematopoiesis of indeterminate potential [CHIP]) [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/107866.html" rel="external">
          "Clonal hematopoiesis of indeterminate potential (CHIP) and related disorders of clonal hematopoiesis", section on 'Clonal hematopoiesis of indeterminate potential (CHIP)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most common karyotypic abnormality is 6pUPD (acquired uniparental disomy with loss of heterozygosity in the short arm of chromosome 6); others include abnormalities of chromosomes 7 and/or 13 [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CAUSES
         </span>
         <span class="headingEndMark">
          —
         </span>
         AA is a specific disease entity reflecting a deficiency of hematopoietic stem cells (HSC) that results in peripheral pancytopenia and bone marrow aplasia  (
         <a class="graphic graphic_table graphicRef70072" href="/z/d/graphic/70072.html" rel="external">
          table 1
         </a>
         ). Most patients have no identified underlying cause and are classified as idiopathic, but the majority of patients with AA appear to have a component of autoimmune destruction of HSCs.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Drugs, radiation, toxins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Exposure to large doses of cytotoxic medications and/or ionizing radiation causes predictable, dose-dependent damage to HSCs and acute hematopoietic failure [
         <a href="#rid4">
          4,43
         </a>
         ]. Such predictable, transient bone marrow suppression is not considered AA.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Drugs can cause bone marrow aplasia either as a dose-dependent effect (eg, cytotoxic chemotherapy) or as an idiosyncratic reaction  (
         <a class="graphic graphic_table graphicRef70072" href="/z/d/graphic/70072.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         The extent and timing of bone marrow suppression to chemotherapy and other cytotoxic drugs is generally predictable and is not considered AA. Peripheral blood cell counts may reach a nadir 7 to 10 days after drug administration and recover to near baseline values within 14 to 28 days.
        </p>
        <p>
         Other drugs that reduce blood cell production as a predictable effect include certain immunosuppressive agents (eg,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ), anti-inflammatory medications (eg, phenylbutazone, gold), and certain antibiotics (eg,
         <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">
          chloramphenicol
         </a>
         ; see below).
        </p>
        <p>
         In contrast, idiosyncratic reactions to drugs are associated with less predictable patterns of bone marrow aplasia. In some cases, cytopenias arise while the patient is still taking the medication. In other cases, the effects are not recognized until days or weeks after exposure. The unpredictable response in such idiosyncratic reactions can make it challenging to indict a particular drug as the cause of AA.
        </p>
        <p>
         Many drugs, including sulfonamides, antiseizure medications (eg,
         <a class="drug drug_general" data-topicid="8934" href="/z/d/drug information/8934.html" rel="external">
          felbamate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         ), and
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         have been associated with AA  (
         <a class="graphic graphic_table graphicRef70072" href="/z/d/graphic/70072.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid4">
          4,5,44-47
         </a>
         ]. The vast majority of patients exposed to these drugs do not develop AA, and the reason for idiosyncratic reactions is unknown. The only potential predisposing factors that have been identified are mutations in genes encoding cellular efflux pumps (eg, P-glycoprotein 1) or drug metabolizing enzymes (eg, glutathione-S-transferase) [
         <a href="#rid48">
          48-53
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">
          Chloramphenicol
         </a>
         is associated with both idiosyncratic and predictable bone marrow suppression. An idiosyncratic reaction to chloramphenicol causes irreversible bone marrow aplasia in approximately 1 of every 20,000 patients, with a sudden onset several months after therapy [
         <a href="#rid5">
          5
         </a>
         ]. Chloramphenicol is also associated with predictable, reversible dose-related bone marrow suppression in virtually all patients due to a direct toxic effect on bone marrow erythroid precursors; this is manifest as a ring of vacuoles around the proerythroblast nucleus and is associated with increased serum iron, because iron is inefficiently utilized for hemoglobin synthesis.
        </p>
        <p class="headingAnchor" id="H435797312">
         <span class="h3">
          Ionizing radiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ionizing radiation has a predictable, dose-dependent bone marrow suppressive effect, which is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6589.html" rel="external">
          "Clinical manifestations, evaluation, and diagnosis of acute radiation exposure", section on 'Biologic effects of radiation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Toxins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Solvents/Degreasing agents, industrial chemicals, insecticides (eg,
         <a class="drug drug_general" data-topicid="9562" href="/z/d/drug information/9562.html" rel="external">
          lindane
         </a>
         ), and pesticides are considered significant risk factors for development of severe AA, based on case-control and other population-based studies [
         <a href="#rid6">
          6,54-57
         </a>
         ]. Prolonged exposure to benzene is particularly notorious in this regard, but benzene and pesticides account for only a small number of AA cases [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Viral infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain viruses are associated with AA. In some cases, viral infection is thought to alter antigens on bone marrow cells and activate a cytotoxic T cell clone or initiate T cell release of cytokines.
        </p>
        <p>
         Hepatitis viruses and human immunodeficiency virus (HIV) can cause severe bone marrow aplasia [
         <a href="#rid58">
          58,59
         </a>
         ]. The mechanism may involve T cell activation with release of cytokines [
         <a href="#rid60">
          60
         </a>
         ], or activation of a cytotoxic T cell clone that recognizes similar target antigens on both liver and bone marrow cells [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
         Hepatitis-associated AA generally develops two to three months after an episode of acute hepatitis and most often affects boys and young men [
         <a href="#rid59">
          59,62
         </a>
         ]. Hepatitis may account for 5 to 10 percent of cases of AA, but the responsible virus has not been identified; hepatitis A, B, C, and G appear not to be involved [
         <a href="#rid59">
          59,62,63
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5923.html" rel="external">
          "Treatment of acquired aplastic anemia in children and adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2253001395">
         <span class="h2">
          Acquired clonal abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Development of clonal abnormalities in blood cells during the course of an individual's life (ie, from mutations that are not transmitted in the germline) are associated with some cases of AA.
        </p>
        <p>
         AA may coexist with or evolve into other disorders, such as paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndromes (MDS), or acute myeloid leukemia (AML). In some cases, immune destruction of the aberrant HSCs contributes to the cytopenias. (See
         <a class="local">
          'Clonal evolution'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H13878766">
         <span class="h3">
          Paroxysmal nocturnal hemoglobinuria
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is a close relationship between AA and PNH, a clonal disorder in which acquired mutations of the
         <em>
          PIG-A
         </em>
         gene can lead to global absence of certain proteins (eg, CD59) on the surface of blood cells, thereby altering their immune appearance and reducing their ability to resist destruction by complement. (See
         <a class="medical medical_review" href="/z/d/html/7156.html" rel="external">
          "Pathogenesis of paroxysmal nocturnal hemoglobinuria"
         </a>
         .)
        </p>
        <p>
         This association may become evident when hemolysis or thrombosis suggestive of PNH is seen in a patient with AA, or when PNH evolves into bone marrow hypoplasia characteristic of AA.
        </p>
        <p>
         Expanded populations of blood cells with the PNH defect have been detected by flow cytometry in approximately half of patients with AA [
         <a href="#rid64">
          64
         </a>
         ]. The abnormal blood cells are thought to initiate an immune response that damages HSCs and other hematopoietic precursors [
         <a href="#rid65">
          65-70
         </a>
         ]. In one prospective study in adults, flow cytometry detected a population of PNH-type cells (range: 0.005 to 23 percent) in 68 percent of 122 patients with newly diagnosed AA [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H564685326">
         <span class="h3">
          Myelodysplastic syndromes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chromosomal abnormalities that are characteristic of MDS are observed in a minority of patients with AA (estimated at 5 to 15 percent) [
         <a href="#rid41">
          41
         </a>
         ]. Dysplastic HSCs of MDS may be subject to immune destruction/suppression by T lymphocytes and lead to bone marrow hypoplasia that is characteristic of AA.
        </p>
        <p>
         A subset of patients with MDS have hypoplastic bone marrow, which shares some features with AA/PNH. This entity and its management are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4542.html" rel="external">
          "Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'Hypoplastic MDS or PNH+'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2907016104">
         <span class="h2">
          Inherited genetic abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some inherited genetic disorders that cause AA have characteristic somatic phenotypes and are easily recognized. Others are identified only after genetic studies find a diagnostic mutation.
        </p>
        <p class="headingAnchor" id="H13878708">
         <span class="h3">
          Fanconi anemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common form of inherited AA is Fanconi anemia (FA), a condition characterized by pancytopenia, predisposition to malignancy, and physical abnormalities (eg, short stature, microcephaly, developmental delay, café-au-lait skin lesions, other characteristic malformations). Diagnosis is usually made in childhood but, because of variable disease manifestations, some individuals may not be diagnosed with FA until adulthood [
         <a href="#rid71">
          71
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/109795.html" rel="external">
          "Clinical manifestations and diagnosis of Fanconi anemia", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         Defining FA as the cause of AA has important implications for management. Individuals with FA should undergo special surveillance for both hematologic and non-hematologic malignancies and require reduced doses of chemotherapy for cancer treatment and/or conditioning therapy for hematopoietic cell transplantation (HCT). Siblings with FA must be excluded as potential HCT donors. (See
         <a class="medical medical_review" href="/z/d/html/109777.html" rel="external">
          "Management and prognosis of Fanconi anemia", section on 'Testing of siblings and management of heterozygotes'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1216245896">
         <span class="h3">
          Shwachman-Diamond syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Shwachman-Diamond syndrome (SDS) usually presents in infancy with bone marrow failure, exocrine pancreatic dysfunction, and skeletal anomalies. AA is seen in patients with SDS, although intermittent neutropenia is the most common hematologic manifestation.
        </p>
        <p>
         The clinical manifestations, genetic basis, and treatment of SDS are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5914.html" rel="external">
          "Shwachman-Diamond syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3376869735">
         <span class="h3">
          Abnormal thrombopoietin or its receptor
         </span>
         <span class="headingEndMark">
          —
         </span>
         AA is associated with inherited conditions that may manifest as congenital amegakaryocytic thrombocytopenia (CAMT). Examples include mutations of thrombopoietin (
         <em>
          THPO
         </em>
         ) [
         <a href="#rid72">
          72
         </a>
         ] or the thrombopoietin receptor (
         <em>
          MPL
         </em>
         ) [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H562764939">
         <span class="h3">
          Dyskeratosis congenita and other telomere abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Blood cells of patients with AA frequently have short telomeres [
         <a href="#rid74">
          74
         </a>
         ]. Inherited and acquired forms of telomere abnormalities that are associated with AA include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dyskeratosis congenita
         </strong>
         – Dyskeratosis congenita (DC) is an inherited cause of AA that is associated with characteristic skin and nail findings  (
         <a class="graphic graphic_picture graphicRef76566" href="/z/d/graphic/76566.html" rel="external">
          picture 1
         </a>
         ), pulmonary fibrosis, cancer predisposition, and additional somatic abnormalities  (
         <a class="graphic graphic_table graphicRef81497" href="/z/d/graphic/81497.html" rel="external">
          table 3
         </a>
         ). The age of onset of DC is variable, and some clinical presentations are subtle.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           TERT
          </em>
         </strong>
         <strong>
          or
         </strong>
         <strong>
          <em>
           TERC
          </em>
         </strong>
         <strong>
          mutations
         </strong>
         – Acquired mutations in
         <em>
          TERT
         </em>
         and other genes in the telomere repair pathway appear to be genetic risk factors for the development of bone marrow failure, possibly by making bone marrow vulnerable to environmental insults (eg, drugs, viruses) and/or altering their immunologic appearance thereby making them susceptible to autoimmune destruction.
        </p>
        <p>
        </p>
        <p>
         DC and related disorders are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/100663.html" rel="external">
          "Dyskeratosis congenita and other telomere biology disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H17841406">
         <span class="h2">
          Symptoms and signs
         </span>
         <span class="headingEndMark">
          —
         </span>
         The patient with AA most commonly presents with recurrent infections due to neutropenia, mucosal hemorrhage or menorrhagia due to thrombocytopenia, or fatigue and cardiopulmonary findings associated with progressive anemia. Infections are typically bacterial, including sepsis, pneumonia, skin infections (cellulitis, abscess), and urinary tract infection; invasive fungal infection is a common cause of death, especially in subjects with prolonged and severe neutropenia [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
         Some patients present with hemolytic anemia or thrombosis that may suggest co-existent paroxysmal nocturnal hemoglobinuria (PNH). (See
         <a class="local">
          'Acquired clonal abnormalities'
         </a>
         above.)
        </p>
        <p>
         Other patients (mostly children) have somatic manifestations associated with specific inherited syndromes (eg, short stature, microcephaly, developmental delay, skin and nail lesions). However, some adults with AA may also manifest characteristic somatic abnormalities (eg, fingernail dystrophy associated with dyskeratosis congenita) due to a previously unrecognized inherited disorder. (See
         <a class="local">
          'Inherited genetic abnormalities'
         </a>
         above.)
        </p>
        <p>
         Other patients are asymptomatic and present with abnormal blood counts.
        </p>
        <p class="headingAnchor" id="H3623932926">
         <span class="h2">
          Complete blood count
         </span>
         <span class="headingEndMark">
          —
         </span>
         The complete blood count reveals pancytopenia (ie, neutropenia, thrombocytopenia, and anemia) along with reticulocytopenia. The peripheral blood smear typically reveals normocytic red blood cells, but they may be macrocytic (ie, mean cell volume &gt;100 fL). Abnormal cells (eg, myeloblasts, atypical lymphoid cells) are not present unless there is an associated hematologic disorder. (See
         <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">
          "Diagnostic approach to anemia in adults"
         </a>
         and
         <a class="local">
          'Clonal evolution'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2554250">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evaluation of a patient with a complete blood count suggestive of AA should establish the diagnosis of AA, seek to identify an underlying cause, and distinguish it from other categories of pancytopenia. Bone marrow biopsy is required to establish the diagnosis of AA.
        </p>
        <p class="headingAnchor" id="H3744196046">
         <span class="h2">
          Urgency of evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The urgency of clinical evaluation and bone marrow biopsy is guided by the depth of cytopenias and the patient's clinical status.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If critical cytopenias and/or potentially life-threatening complications (eg, infection, bleeding, cardiorespiratory compromise) are present  (
         <a class="graphic graphic_table graphicRef112135" href="/z/d/graphic/112135.html" rel="external">
          table 4
         </a>
         ), the patient should undergo immediate hematology consultation (including bone marrow biopsy) and hospitalization. Further discussion of assessment and management of such conditions is provided separately. (See
         <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">
          "Approach to the adult with pancytopenia", section on 'Emergencies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with milder cytopenias and no clinical complications, it
         <strong>
          may
         </strong>
         <strong>
          not
         </strong>
         be essential to immediately hospitalize, obtain hematology consultation, and/or perform bone marrow examination. In such a setting, close observation and monitoring of blood counts (eg, over days to a few weeks) may reveal a reversible cause of cytopenias (eg, due to recent viral infection). However, evaluation should proceed promptly if no improvement is observed and/or complications of cytopenias arise.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3302405455">
         <span class="h2">
          History, examination, laboratory studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         The history may provide clues to an underlying etiology (eg, exposure to drugs/chemicals, hepatitis, or other viral infections). Family history (in both children and adults) may reveal other family members with cytopenias and/or somatic findings suggestive of an inherited disorder.
        </p>
        <p>
         Physical findings are generally consistent with pancytopenia, especially pallor and petechiae. The liver, spleen, and lymph nodes are not typically enlarged in AA; such findings suggest an alternative diagnosis. There may be overt or subtle manifestations of inherited disorders (eg, cutaneous/nail findings, short stature, skeletal or genitourinary abnormalities, eye/ear findings). Physical examination should also evaluate and assess potential complications of the cytopenias (eg, cardiovascular system, evidence of infections). (See
         <a class="medical medical_review" href="/z/d/html/109795.html" rel="external">
          "Clinical manifestations and diagnosis of Fanconi anemia", section on 'Clinical features'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/100663.html" rel="external">
          "Dyskeratosis congenita and other telomere biology disorders", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         Serum chemistries, including electrolytes, liver function tests (including lactate dehydrogenase [LDH]), and renal function tests should be performed to identify associated conditions and complications (eg, hemolysis), and help to distinguish AA from other causes of pancytopenia. Serum vitamin B12 and red blood cell folate levels should be performed to exclude those causes of megaloblastic anemia. (See
         <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">
          "Approach to the adult with pancytopenia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Bone marrow examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bone marrow aspiration and biopsy is required to establish the diagnosis of AA and exclude other causes of pancytopenia. The biopsy should be performed at a site that has not suffered prior direct damage (eg, radiation, trauma, infection). (See
         <a class="medical medical_review" href="/z/d/html/4436.html" rel="external">
          "Bone marrow aspiration and biopsy: Indications and technique", section on 'Choice of aspiration or biopsy site'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4434.html" rel="external">
          "Evaluation of bone marrow aspirate smears", section on 'Sample preparation'
         </a>
         .)
        </p>
        <p>
         Diagnostic findings from bone marrow examination include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The bone marrow is profoundly hypocellular with a decrease in all elements; the marrow space is composed mostly of fat cells and marrow stroma  (
         <a class="graphic graphic_picture graphicRef63867" href="/z/d/graphic/63867.html" rel="external">
          picture 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Residual hematopoietic cells are morphologically normal, and hematopoiesis is not megaloblastic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infiltration of the bone marrow with malignant cells or fibrosis is not present.
        </p>
        <p>
        </p>
        <p>
         Bone marrow specimens should undergo cytogenetic, molecular, and other specialized testing, as described below.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Diagnostic criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         AA is defined as pancytopenia with a hypocellular bone marrow in the absence of an abnormal infiltrate or marrow fibrosis.
        </p>
        <p>
         There is no required duration of cytopenias to establish a diagnosis of AA. However, if a specific cause of cytopenias is identified (eg, cytotoxic chemotherapy, viral infection), the blood counts may be monitored for days to several weeks to permit recovery and determine if the insult is reversible.
        </p>
        <p>
         For purposes of risk stratification and selection of therapy, AA is classified according to the following criteria:
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h3">
          Severe AA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnosis of severe aplastic anemia (SAA) requires both of the following criteria [
         <a href="#rid76">
          76
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bone marrow cellularity &lt;25 percent (or 25 to 50 percent if &lt;30 percent of residual cells are hematopoietic)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At least two of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Peripheral blood absolute neutrophil count (ANC) &lt;500/microL (&lt;0.5 X 10
         <sup>
          9
         </sup>
         /L)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Peripheral blood platelet count &lt;20,000/microL
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Peripheral blood reticulocyte count &lt;60,000/microL; some centers use a threshold of &lt;50,000/microL
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h3">
          Very severe AA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnosis of very severe aplastic anemia (vSAA) include the criteria for SAA (above) and ANC is &lt;200/microL (
         <a class="calc calc_professional" href="/z/d/html/13483.html" rel="external">
          calculator 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H762960190">
         <span class="h3">
          Non-severe AA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Criteria for non-severe AA are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypocellular bone marrow (as described for SAA)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral blood cytopenias not fulfilling criteria for SAA or vSAA (see above)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2852360116">
         <span class="h2">
          Specialized testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The decision to perform specialized testing is influenced by the clinical setting (eg, adult versus child, findings consistent with an inherited syndrome).
        </p>
        <p>
         <strong>
          In all adults
         </strong>
         with AA, the following specialized testing should be performed to detect coexistent disorders, such as paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, or acute leukemia:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flow cytometry for assessment of cell surface CD59 on peripheral blood red blood cells or neutrophils. (See
         <a class="medical medical_review" href="/z/d/html/7159.html" rel="external">
          "Clinical manifestations and diagnosis of paroxysmal nocturnal hemoglobinuria"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cytogenetic and molecular testing of bone marrow. (See
         <a class="medical medical_review" href="/z/d/html/4500.html" rel="external">
          "Genetic abnormalities in hematologic and lymphoid malignancies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         <strong>
          In all
         </strong>
         <strong>
          children
         </strong>
         with AA we suggest genetic testing (eg,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=7152" target="_blank">
          Genetic Testing Registry
         </a>
         ) to identify inherited genetic abnormalities. Descriptions of inherited syndromes associated with AA and diagnostic testing are discussed in greater detail separately. (See
         <a class="local">
          'Inherited genetic abnormalities'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/109795.html" rel="external">
          "Clinical manifestations and diagnosis of Fanconi anemia", section on 'Genetic testing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/100663.html" rel="external">
          "Dyskeratosis congenita and other telomere biology disorders", section on 'Laboratory testing and bone marrow'
         </a>
         .)
        </p>
        <p>
         <strong>
          In some adults
         </strong>
         with AA we suggest genetic testing, because cytopenias may be the first manifestation of an inherited disorder. The diagnosis may be straightforward in adult patients with characteristic abnormalities (eg, short stature, skeletal abnormalities, skin/nail lesions), but only subtle nonhematologic abnormalities may be seen in others. Testing should be performed when there is such suspicion. (See
         <a class="medical medical_review" href="/z/d/html/109795.html" rel="external">
          "Clinical manifestations and diagnosis of Fanconi anemia", section on 'Clinical features'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/100663.html" rel="external">
          "Dyskeratosis congenita and other telomere biology disorders", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         Testing for an inherited disorder should also be considered in adults with AA who fail to respond to treatment with anti-thymocyte globulin (ATG). (See
         <a class="medical medical_review" href="/z/d/html/7158.html" rel="external">
          "Treatment of aplastic anemia in adults", section on 'Pretreatment evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of AA includes other causes of pancytopenia, such as megaloblastic anemia, bone marrow infiltration (eg, myelofibrosis, various cancers), sequestration/redistribution (eg, hypersplenism), and certain myeloid malignancies (eg, myelodysplastic syndrome [MDS], acute myeloid leukemia [AML]). The evaluation of pancytopenia due to these other causes is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">
          "Approach to the adult with pancytopenia"
         </a>
         .)
        </p>
        <p>
         Physical examination, review of the peripheral blood smear, and bone marrow aspirate/biopsy can distinguish some of these disorders from AA, but more specialized testing (eg, cytogenetic or molecular diagnostics) is often required.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Megaloblastic anemia
         </strong>
         – Megaloblastic anemia (eg, pernicious anemia, malnutrition) can cause profound pancytopenia and bone marrow hypoplasia, most commonly due to deficiencies of vitamin B12 and/or folate. Megaloblastic anemia is characterized by the presence of hypersegmented neutrophils and macro-ovalocytes on the peripheral blood smear and megaloblastic changes in the bone marrow examination; serum levels of vitamin B12 and/or folate can confirm these diagnoses. (See
         <a class="medical medical_review" href="/z/d/html/7155.html" rel="external">
          "Clinical manifestations and diagnosis of vitamin B12 and folate deficiency"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infiltrative disorders
         </strong>
         – Infiltration of the bone marrow by fibrosis (eg, myeloproliferative neoplasms such as primary myelofibrosis), malignancies (eg, MDS, AML, lymphoma, multiple myeloma, carcinoma), or infectious agents (eg, tuberculosis, fungi) may cause pancytopenia by bone marrow replacement and/or sequestration/redistribution of blood cells. These disorders can usually be distinguished from AA by the presence of myelophthisic changes on the peripheral blood smear (eg, schistocytes, nucleated red blood cells) and morphologic, cytogenetic, and/or molecular abnormalities of the bone marrow. (See
         <a class="medical medical_review" href="/z/d/html/4529.html" rel="external">
          "Clinical manifestations and diagnosis of primary myelofibrosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reversible bone marrow suppression
         </strong>
         – Predictable, dose-dependent effects of cytotoxic chemotherapy or radiation therapy, overwhelming sepsis, or acute viral infection can cause transient, reversible pancytopenia with hypoplastic bone marrow. Such diagnoses are established by history and laboratory studies (eg, microbiologic and serologic testing), and serial examinations of blood counts should demonstrate improvements in days to weeks. If a bone marrow aspirate/biopsy is planned, it is important to perform it away from sites of prior radiation treatment or other bone marrow injury.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypersplenism
         </strong>
         – Hypersplenism refers to cytopenias due to splenomegaly and may be caused by liver cirrhosis, portal vein thrombosis, and bone marrow infiltrative disorders. Splenomegaly alone rarely causes the degree of cytopenias seen with infiltrative bone marrow disorders or AA. These diagnoses can be assessed by clinical evaluation and imaging studies; bone marrow examination is expected to reveal adequate (or increased) hematopoietic activity. (See
         <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">
          "Approach to the adult with pancytopenia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypoplastic MDS
         </strong>
         – The hypocellular variant of MDS can be very difficult to distinguish from AA. The diagnosis is established by demonstration of dysplastic changes in bone marrow and/or cytogenetic or molecular abnormalities that are characteristic of MDS. There is clinical overlap between hypoplastic MDS and AA, and many cases of the former will respond to immunosuppressive therapies that are used for treatment of AA. (See
         <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">
          "Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Large granular lymphocyte leukemia
         </strong>
         – Large granular lymphocyte (LGL) leukemia is a clonal disease characterized by cytopenias, splenomegaly, and infiltration of peripheral blood and bone marrow by LGLs. The malignant lymphocytes have characteristic azurophilic granules  (
         <a class="graphic graphic_picture graphicRef69027" href="/z/d/graphic/69027.html" rel="external">
          picture 3
         </a>
         ), and their presence can be confirmed by flow cytometry and molecular testing. AA and LGL leukemia can coexist, but the presence of substantial numbers of clonal LGL cells will confirm the latter diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/16360.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2453669266">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120173.html" rel="external">
          "Society guideline links: Bone marrow failure syndromes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31407997">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/82989.html" rel="external">
          "Patient education: Aplastic anemia (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Aplastic anemia (AA) is a bone marrow failure (BMF) disorder characterized by pancytopenia with bone marrow hypoplasia/aplasia due to loss of hematopoietic stem cells (HSCs).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathophysiology
         </strong>
         – Most cases of AA are described as idiopathic because there is no identifiable cause; such cases are thought to result from autoimmune damage to HSCs. (See
         <a class="local">
          'Causes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         BMF can also be caused by drugs, chemicals, radiation, viral infection, nutritional deficiency (eg, folate or vitamin B12), or inherited genetic disorders  (
         <a class="graphic graphic_table graphicRef70072" href="/z/d/graphic/70072.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Presentation
         </strong>
         – Patients with AA generally present with clinical findings related to pancytopenia, such as fatigue, dyspnea, fever, infections, or bleeding/bruising. Some patients are asymptomatic and are first detected by laboratory studies. Characteristic somatic abnormalities (eg, skeletal anomalies, short stature, microcephaly, skin/nail findings) may be present in individuals with inherited BMF  (
         <a class="graphic graphic_table graphicRef81497" href="/z/d/graphic/81497.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial evaluation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical
         </strong>
         – History should include cytopenia-related symptoms (described above) and the duration and depth of cytopenias, if known. Recent viral infections, diet, drug and chemical exposure, and liver disease should be documented. Examination should evaluate lymphadenopathy, enlargement of liver and spleen, mucosal ulcers, and signs of infection or bleeding. Individuals with an inherited BMF disorder may have somatic anomalies (described above) that can be subtle. (See
         <a class="local">
          'History, examination, laboratory studies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Laboratory
         </strong>
         – Complete blood count (CBC), reticulocyte count, and blood smear should be performed when AA is suspected.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          CBC and reticulocyte count
         </strong>
         – Red blood cells (RBCs) are generally normocytic or macrocytic, there are few mature neutrophils, most white blood cells (WBCs) are lymphocytes, and platelets are decreased on the CBC. The reticulocyte count is inappropriately low.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Blood smear
         </strong>
         – Cells are generally normal, except for cytopenias; no blasts are seen. Megaloblastic changes of RBCs and WBCs  (
         <a class="graphic graphic_picture graphicRef70609" href="/z/d/graphic/70609.html" rel="external">
          picture 4
         </a>
         ) may be seen with folate or vitamin B12 deficiency.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         – AA should be suspected in a patient with cytopenias in two or more blood lineages or with related clinical findings (described above). The diagnosis of AA requires bone marrow (BM) examination, the urgency of which is guided by the patient's clinical status and severity of cytopenias.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Certain critical cytopenias or life-threatening complications may require immediate management and/or hospitalization  (
         <a class="graphic graphic_table graphicRef112135" href="/z/d/graphic/112135.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of AA is based on a profoundly hypocellular/aplastic bone marrow biopsy, morphologically normal residual hematopoietic cells, and no infiltration with malignant cells or fibrosis. The marrow space is mostly composed of fat cells and marrow stroma  (
         <a class="graphic graphic_picture graphicRef63867" href="/z/d/graphic/63867.html" rel="external">
          picture 2
         </a>
         ). (See
         <a class="local">
          'Bone marrow examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Criteria for diagnosis and grading AA as severe, very severe, and non-severe are presented above. (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – Idiopathic AA is distinguished from other causes of pancytopenia  (
         <a class="graphic graphic_table graphicRef52354" href="/z/d/graphic/52354.html" rel="external">
          table 2
         </a>
         ) by clinical evaluation, laboratory studies, and bone marrow examination from other causes of bone marrow failure, including (see
         <a class="local">
          'Differential diagnosis'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Megaloblastic anemia (eg, deficiency of folate or vitamin B12)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bone marrow failure from infiltrative disorders (eg, fibrosis, cancer)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Transient bone marrow suppression from cytotoxic drugs, radiation, viral infection
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypoplastic myelodysplastic syndrome (MDS)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Large granular lymphocyte disorders
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H683870569">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editors of UpToDate acknowledge the contributions of Stanley L Schrier, MD as author on this topic, his tenure as the founding Editor-in-Chief for UpToDate in Hematology, and his dedicated and longstanding involvement with the UpToDate program.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Peffault de Latour R, Peters C, Gibson B, et al. Recommendations on hematopoietic stem cell transplantation for inherited bone marrow failure syndromes. Bone Marrow Transplant 2015; 50:1168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 2016; 172:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young NS, Scheinberg P, Calado RT. Aplastic anemia. Curr Opin Hematol 2008; 15:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young NS. Acquired aplastic anemia. Ann Intern Med 2002; 136:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallerstein RO, Condit PK, Kasper CK, et al. Statewide study of chloramphenicol therapy and fatal aplastic anemia. JAMA 1969; 208:2045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Issaragrisil S, Kaufman DW, Anderson T, et al. The epidemiology of aplastic anemia in Thailand. Blood 2006; 107:1299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy M, Kelly JP, Kaufman DW, Shapiro S. Risk of agranulocytosis and aplastic anemia in relation to history of infectious mononucleosis: a report from the international agranulocytosis and aplastic anemia study. Ann Hematol 1993; 67:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young NS, Kaufman DW. The epidemiology of acquired aplastic anemia. Haematologica 2008; 93:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young NS. Aplastic Anemia. N Engl J Med 2018; 379:1643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheinberg P, Chen J. Aplastic anemia: what have we learned from animal models and from the clinic. Semin Hematol 2013; 50:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walport MJ, Hubbard WN, Hughes GR. Reversal of aplastic anaemia secondary to systemic lupus erythematosus by high-dose intravenous cyclophosphamide. Br Med J (Clin Res Ed) 1982; 285:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nissen C. The pathophysiology of aplastic anemia. Semin Hematol 1991; 28:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffman R, Young N, Ershler WB, et al. Diffuse fasciitis and aplastic anemia: a report of four cases revealing an unusual association between rheumatologic and hematologic disorders. Medicine (Baltimore) 1982; 61:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Masson A, Bouaziz JD, Peffault de Latour R, et al. Severe aplastic anemia associated with eosinophilic fasciitis: report of 4 cases and review of the literature. Medicine (Baltimore) 2013; 92:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomou EE, Rezvani K, Mielke S, et al. Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood 2007; 110:1603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shi J, Ge M, Lu S, et al. Intrinsic impairment of CD4(+)CD25(+) regulatory T cells in acquired aplastic anemia. Blood 2012; 120:1624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirano N, Butler MO, Von Bergwelt-Baildon MS, et al. Autoantibodies frequently detected in patients with aplastic anemia. Blood 2003; 102:4567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feng X, Chuhjo T, Sugimori C, et al. Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood 2004; 104:2425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeng W, Maciejewski JP, Chen G, et al. Selective reduction of natural killer T cells in the bone marrow of aplastic anaemia. Br J Haematol 2002; 119:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanaoka N, Nakakuma H, Horikawa K, et al. NKG2D-mediated immunity underlying paroxysmal nocturnal haemoglobinuria and related bone marrow failure syndromes. Br J Haematol 2009; 146:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirano N, Butler MO, Guinan EC, et al. Presence of anti-kinectin and anti-PMS1 antibodies in Japanese aplastic anaemia patients. Br J Haematol 2005; 128:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takamatsu H, Feng X, Chuhjo T, et al. Specific antibodies to moesin, a membrane-cytoskeleton linker protein, are frequently detected in patients with acquired aplastic anemia. Blood 2007; 109:2514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goto M, Kuribayashi K, Takahashi Y, et al. Identification of autoantibodies expressed in acquired aplastic anaemia. Br J Haematol 2013; 160:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomou EE, Keyvanfar K, Young NS. T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood 2006; 107:3983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li J, Zhao Q, Xing W, et al. Interleukin-27 enhances the production of tumour necrosis factor-α and interferon-γ by bone marrow T lymphocytes in aplastic anaemia. Br J Haematol 2011; 153:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maciejewski JP, Selleri C, Sato T, et al. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br J Haematol 1995; 91:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dufour C, Capasso M, Svahn J, et al. Homozygosis for (12) CA repeats in the first intron of the human IFN-gamma gene is significantly associated with the risk of aplastic anaemia in Caucasian population. Br J Haematol 2004; 126:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ismail M, Gibson FM, Gordon-Smith EC, Rutherford TR. Bcl-2 and Bcl-x expression in the CD34+ cells of aplastic anaemia patients: relationship with increased apoptosis and upregulation of Fas antigen. Br J Haematol 2001; 113:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vibhuti, Tripathy NK, Nityanand S. Massive apoptosis of bone marrow cells in aplastic anaemia. Br J Haematol 2002; 117:993.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu JL, Nagasaka T, Nakashima N. Involvement of cytotoxic granules in the apoptosis of aplastic anaemia. Br J Haematol 2003; 120:850.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nisticò A, Young NS. gamma-Interferon gene expression in the bone marrow of patients with aplastic anemia. Ann Intern Med 1994; 120:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sloand E, Kim S, Maciejewski JP, et al. Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood 2002; 100:1185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurion R, Gafter-Gvili A, Paul M, et al. Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica 2009; 94:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tichelli A, Schrezenmeier H, Socié G, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood 2011; 117:4434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tichelli A, Socié G, Henry-Amar M, et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Ann Intern Med 1999; 130:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaito K, Kobayashi M, Katayama T, et al. Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults. Br J Haematol 1998; 103:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997; 90:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Socié G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med 1993; 329:1152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peinemann F, Bartel C, Grouven U. First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia. Cochrane Database Syst Rev 2013; :CD006407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Socie G, Mary JY, Schrezenmeier H, et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood 2007; 109:2794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogawa S. Clonal hematopoiesis in acquired aplastic anemia. Blood 2016; 128:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abkowitz JL. Clone wars--the emergence of neoplastic blood-cell clones with aging. N Engl J Med 2014; 371:2523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LANGE RD, WRIGHT SW, TOMONAGA M, et al. Refractory anemia occurring in survivors of the atomic bombing in Nagasaki, Japan. Blood 1955; 10:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kay AG. Myelotoxicity of gold. Br Med J 1976; 1:1266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brodie MJ, Pellock JM. Taming the brain storms: felbamate updated. Lancet 1995; 346:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laporte JR, Ibáñez L, Ballarín E, et al. Fatal aplastic anaemia associated with nifedipine. Lancet 1998; 352:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Handoko KB, Souverein PC, van Staa TP, et al. Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia 2006; 47:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calado RT, Garcia AB, Falcão RP. Decreased activity of the multidrug resistance P-glycoprotein in acquired aplastic anaemia: possible pathophysiologic implications. Br J Haematol 1998; 102:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calado RT, Garcia AB, Gallo DA, Falcão RP. Reduced function of the multidrug resistance P-glycoprotein in CD34+ cells of patients with aplastic anaemia. Br J Haematol 2002; 118:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Babushok DV, Li Y, Roth JJ, et al. Common polymorphic deletion of glutathione S-transferase theta predisposes to acquired aplastic anemia: Independent cohort and meta-analysis of 609 patients. Am J Hematol 2013; 88:862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutton JF, Stacey M, Kearns WG, et al. Increased risk for aplastic anemia and myelodysplastic syndrome in individuals lacking glutathione S-transferase genes. Pediatr Blood Cancer 2004; 42:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dufour C, Svahn J, Bacigalupo A, et al. Genetic polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 and the risk of acquired idiopathic aplastic anemia in Caucasian patients. Haematologica 2005; 90:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerson WT, Fine DG, Spielberg SP, Sensenbrenner LL. Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro. Blood 1983; 61:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muir KR, Chilvers CE, Harriss C, et al. The role of occupational and environmental exposures in the aetiology of acquired severe aplastic anaemia: a case control investigation. Br J Haematol 2003; 123:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SCOTT JL, CARTWRIGHT GE, WINTROBE MM. Acquired aplastic anemia: an analysis of thirty-nine cases and review of the pertinent literature. Medicine (Baltimore) 1959; 38:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powars D. Aplastic anemia secondary to glue sniffing. N Engl J Med 1965; 273:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LOGE JP. APLASTIC ANEMIA FOLLOWING EXPOSURE TO BENZENE HEXACHLORIDE (LINDANE). JAMA 1965; 193:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurtzman G, Young N. Viruses and bone marrow failure. Baillieres Clin Haematol 1989; 2:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown KE, Tisdale J, Barrett AJ, et al. Hepatitis-associated aplastic anemia. N Engl J Med 1997; 336:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu J, Basu A, Melenhorst JJ, et al. Analysis of T-cell repertoire in hepatitis-associated aplastic anemia. Blood 2004; 103:4588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikawa Y, Nishimura R, Kuroda R, et al. Expansion of a liver-infiltrating cytotoxic T-lymphocyte clone in concert with the development of hepatitis-associated aplastic anaemia. Br J Haematol 2013; 161:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Locasciulli A, Bacigalupo A, Bruno B, et al. Hepatitis-associated aplastic anaemia: epidemiology and treatment results obtained in Europe. A report of The EBMT aplastic anaemia working party. Br J Haematol 2010; 149:890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mary JY, Baumelou E, Guiguet M. Epidemiology of aplastic anemia in France: a prospective multicentric study. The French Cooperative Group for Epidemiological Study of Aplastic Anemia. Blood 1990; 75:1646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young NS. Paroxysmal nocturnal hemoglobinuria: current issues in pathophysiology and treatment. Curr Hematol Rep 2005; 4:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mukhina GL, Buckley JT, Barber JP, et al. Multilineage glycosylphosphatidylinositol anchor-deficient haematopoiesis in untreated aplastic anaemia. Br J Haematol 2001; 115:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maciejewski JP, Rivera C, Kook H, et al. Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored protein-deficient clones. Br J Haematol 2001; 115:1015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugimori C, Mochizuki K, Qi Z, et al. Origin and fate of blood cells deficient in glycosylphosphatidylinositol-anchored protein among patients with bone marrow failure. Br J Haematol 2009; 147:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wlodarski MW, Gondek LP, Nearman ZP, et al. Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. Blood 2006; 108:2632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maciejewski JP, Follmann D, Nakamura R, et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood 2001; 98:3513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 2006; 107:1308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huck K, Hanenberg H, Gudowius S, et al. Delayed diagnosis and complications of Fanconi anaemia at advanced age--a paradigm. Br J Haematol 2006; 133:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dasouki MJ, Rafi SK, Olm-Shipman AJ, et al. Exome sequencing reveals a thrombopoietin ligand mutation in a Micronesian family with autosomal recessive aplastic anemia. Blood 2013; 122:3440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walne AJ, Dokal A, Plagnol V, et al. Exome sequencing identifies MPL as a causative gene in familial aplastic anemia. Haematologica 2012; 97:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheinberg P, Cooper JN, Sloand EM, et al. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA 2010; 304:1358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torres HA, Bodey GP, Rolston KV, et al. Infections in patients with aplastic anemia: experience at a tertiary care cancer center. Cancer 2003; 98:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies JK, Guinan EC. An update on the management of severe idiopathic aplastic anaemia in children. Br J Haematol 2007; 136:549.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7152 Version 55.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26052913" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Recommendations on hematopoietic stem cell transplantation for inherited bone marrow failure syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26568159" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Guidelines for the diagnosis and management of adult aplastic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18391779" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11926789" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Acquired aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5818983" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Statewide study of chloramphenicol therapy and fatal aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16254144" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The epidemiology of aplastic anemia in Thailand.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8218540" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Risk of agranulocytosis and aplastic anemia in relation to history of infectious mononucleosis: a report from the international agranulocytosis and aplastic anemia study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18379007" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The epidemiology of acquired aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30354958" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Aplastic Anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24216172" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Aplastic anemia: what have we learned from animal models and from the clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6810992" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Reversal of aplastic anaemia secondary to systemic lupus erythematosus by high-dose intravenous cyclophosphamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1759172" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The pathophysiology of aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7144530" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Diffuse fasciitis and aplastic anemia: a report of four cases revealing an unusual association between rheumatologic and hematologic disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23429351" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Severe aplastic anemia associated with eosinophilic fasciitis: report of 4 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17463169" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22797698" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Intrinsic impairment of CD4(+)CD25(+) regulatory T cells in acquired aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12947009" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Autoantibodies frequently detected in patients with aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15217832" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12437663" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Selective reduction of natural killer T cells in the bone marrow of aplastic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19594748" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : NKG2D-mediated immunity underlying paroxysmal nocturnal haemoglobinuria and related bone marrow failure syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15638857" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Presence of anti-kinectin and anti-PMS1 antibodies in Japanese aplastic anaemia patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17110458" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Specific antibodies to moesin, a membrane-cytoskeleton linker protein, are frequently detected in patients with acquired aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23116149" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Identification of autoantibodies expressed in acquired aplastic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16434488" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21506940" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Interleukin-27 enhances the production of tumour necrosis factor-αand interferon-γby bone marrow T lymphocytes in aplastic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7577642" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15327519" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Homozygosis for (12) CA repeats in the first intron of the human IFN-gamma gene is significantly associated with the risk of aplastic anaemia in Caucasian population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11380462" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Bcl-2 and Bcl-x expression in the CD34+ cells of aplastic anaemia patients: relationship with increased apoptosis and upregulation of Fas antigen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12060143" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Massive apoptosis of bone marrow cells in aplastic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12614221" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Involvement of cytotoxic granules in the apoptosis of aplastic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8311369" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : gamma-Interferon gene expression in the bone marrow of patients with aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12149196" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19336743" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21233311" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10049197" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9827895" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9242530" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8377778" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23881658" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17110459" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27121470" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Clonal hematopoiesis in acquired aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25426835" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Clone wars--the emergence of neoplastic blood-cell clones with aging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14363312" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Refractory anemia occurring in survivors of the atomic bombing in Nagasaki, Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/817772" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Myelotoxicity of gold.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7564721" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Taming the brain storms: felbamate updated.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9746025" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Fatal aplastic anaemia associated with nifedipine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16886988" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Risk of aplastic anemia in patients using antiepileptic drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9753037" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Decreased activity of the multidrug resistance P-glycoprotein in acquired aplastic anaemia: possible pathophysiologic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12100168" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Reduced function of the multidrug resistance P-glycoprotein in CD34+ cells of patients with aplastic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23798465" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Common polymorphic deletion of glutathione S-transferase theta predisposes to acquired aplastic anemia: Independent cohort and meta-analysis of 609 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14752874" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Increased risk for aplastic anemia and myelodysplastic syndrome in individuals lacking glutathione S-transferase genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16079101" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Genetic polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 and the risk of acquired idiopathic aplastic anemia in Caucasian patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6831050" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14632783" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : The role of occupational and environmental exposures in the aetiology of acquired severe aplastic anaemia: a case control investigation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13656164" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Acquired aplastic anemia: an analysis of thirty-nine cases and review of the pertinent literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5827034" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Aplastic anemia secondary to glue sniffing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14304352" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : APLASTIC ANEMIA FOLLOWING EXPOSURE TO BENZENE HEXACHLORIDE (LINDANE).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2537667" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Viruses and bone marrow failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9091802" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Hepatitis-associated aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14988156" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Analysis of T-cell repertoire in hepatitis-associated aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23419100" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Expansion of a liver-infiltrating cytotoxic T-lymphocyte clone in concert with the development of hepatitis-associated aplastic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20456352" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Hepatitis-associated aplastic anaemia: epidemiology and treatment results obtained in Europe. A report of The EBMT aplastic anaemia working party.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2183887" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Epidemiology of aplastic anemia in France: a prospective multicentric study. The French Cooperative Group for Epidemiological Study of Aplastic Anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15720958" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Paroxysmal nocturnal hemoglobinuria: current issues in pathophysiology and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11703352" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Multilineage glycosylphosphatidylinositol anchor-deficient haematopoiesis in untreated aplastic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11843844" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored protein-deficient clones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19656154" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Origin and fate of blood cells deficient in glycosylphosphatidylinositol-anchored protein among patients with bone marrow failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16614248" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11739151" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16179371" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16611311" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Delayed diagnosis and complications of Fanconi anaemia at advanced age--a paradigm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24085763" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Exome sequencing reveals a thrombopoietin ligand mutation in a Micronesian family with autosomal recessive aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22180433" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Exome sequencing identifies MPL as a causative gene in familial aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20858879" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12833460" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Infections in patients with aplastic anemia: experience at a tertiary care cancer center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17214739" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : An update on the management of severe idiopathic aplastic anaemia in children.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
